Recent Updates
Recently added Catalysts

Pedmark

Phase 2

Solid Tumor Malignancies | Small molecule | Oncology |Fennec Pharmaceuticals Inc.|Last Updated: Feb 12, 2026

Target and mechanism

ModalitySmall molecule

Also known as Pedmark® STS, Pedmark STS

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment25

FDA Designations

ORPHAN_DRUG

Clinical trial landscape

Pedmark · 1 trial · 4 indications

Phase 2 1
NCT07407582Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)Solid Tumor Malignancies
NOT YET_RECRUITING25 Analytics
PHASE2NOT YET_RECRUITING
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
Solid Tumor Malignancies
NCT0740758225
Unlock trial analytics

Study Design & Arms

AllocationNA
MaskingNONE
PurposeTREATMENT

Interventions

NameTypeDescription
Pedmark® STSDRUGPedmark® STS (20 g/m2) will be given via intravenous infusion over 15-30 minutes, starting 6 hours after the completion of cisplatin infusion. Pedmark® STS will be given each day of cisplatin infusion.
Unlock Study Design Details